Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single low-dose primaquine added to artesunate-pyronaridine in children with uncomplicated falciparum malaria
ISRCTN16297951Phase 2Completed
- Sponsor
- University of Oxford
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of primaquine, artesunate and pyronaridine in Malaria (2 arms), sponsored by University of Oxford. Primary endpoints: Proportion of patients infecting at least one mosquito and Within-person percentage change in mosquito infectivity. Started Jul 2024; status: completed.
02
Drugs
primaquineartesunatepyronaridine
03
Conditions
Malaria
Beyond the preview
Go deeper on ISRCTN16297951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN16297951.